Benitec Biopharma Inc. (NASDAQ:BNTC) Position Trimmed by Janus Henderson Group PLC

Janus Henderson Group PLC reduced its holdings in Benitec Biopharma Inc. (NASDAQ:BNTC) by 2.7% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 876,523 shares of the biotechnology company’s stock after selling 24,293 shares during the quarter. Janus Henderson Group PLC owned approximately 8.30% of Benitec Biopharma worth $8,033,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. GAMMA Investing LLC boosted its stake in Benitec Biopharma by 53.0% in the second quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 1,884 shares during the period. Acuta Capital Partners LLC acquired a new position in Benitec Biopharma during the 3rd quarter valued at approximately $274,000. Simplify Asset Management Inc. bought a new position in Benitec Biopharma during the 2nd quarter worth $358,000. Nantahala Capital Management LLC bought a new position in Benitec Biopharma during the 2nd quarter worth $5,881,000. Finally, Suvretta Capital Management LLC increased its position in Benitec Biopharma by 422.0% in the third quarter. Suvretta Capital Management LLC now owns 8,829,053 shares of the biotechnology company’s stock worth $81,139,000 after buying an additional 7,137,763 shares during the period. 52.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently commented on BNTC. Piper Sandler restated an “overweight” rating on shares of Benitec Biopharma in a research report on Friday, October 18th. JMP Securities upped their target price on shares of Benitec Biopharma from $16.00 to $18.00 and gave the stock a “market outperform” rating in a research report on Monday, October 14th. Guggenheim restated a “buy” rating and issued a $17.00 price target on shares of Benitec Biopharma in a research note on Tuesday, December 3rd. Finally, Oppenheimer assumed coverage on Benitec Biopharma in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $35.00 target price on the stock. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $22.60.

Benitec Biopharma Stock Performance

Shares of Benitec Biopharma stock opened at $11.23 on Monday. The business has a fifty day simple moving average of $10.32 and a 200-day simple moving average of $9.16. Benitec Biopharma Inc. has a fifty-two week low of $2.69 and a fifty-two week high of $12.89.

Insiders Place Their Bets

In other Benitec Biopharma news, Director Suvretta Capital Management, L bought 42,000 shares of Benitec Biopharma stock in a transaction that occurred on Tuesday, December 3rd. The stock was purchased at an average cost of $9.60 per share, for a total transaction of $403,200.00. Following the completion of the acquisition, the director now owns 7,957,365 shares of the company’s stock, valued at approximately $76,390,704. This represents a 0.53 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is owned by company insiders.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.